AstraZeneca's stock has seen recent volatility, with investor concern over potential BMS merger talks in August and a July heart drug trial failure. However, new positive late-stage COPD drug results (tozorakimab) in September offer a potential boost, as the company aims for its $80 billion 2030 sales target.